Drug Type Bispecific antibody |
Synonyms RG-6333, RO-7443904 |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD28 agonists(T-cell-specific surface glycoprotein CD28 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Hodgkin Lymphoma | Phase 1 | CH | 23 May 2023 | |
B-cell lymphoma refractory | Phase 1 | US | 18 Feb 2022 | |
B-cell lymphoma refractory | Phase 1 | AU | 18 Feb 2022 | |
B-cell lymphoma refractory | Phase 1 | DK | 18 Feb 2022 | |
B-cell lymphoma refractory | Phase 1 | FR | 18 Feb 2022 | |
B-cell lymphoma refractory | Phase 1 | IT | 18 Feb 2022 | |
B-cell lymphoma refractory | Phase 1 | GB | 18 Feb 2022 |